- Home
- MBWM vs RGNX Comparison
MBWM vs RGNX Comparison
Compare MBWM & RGNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MBWM
- RGNX
- Stock Information
- Founded
- MBWM 1997
- RGNX 2008
- Country
- MBWM United States
- RGNX United States
- Employees
- MBWM N/A
- RGNX N/A
- Industry
- MBWM Major Banks
- RGNX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- MBWM Finance
- RGNX Health Care
- Exchange
- MBWM Nasdaq
- RGNX Nasdaq
- Market Cap
- MBWM 740.5M
- RGNX 661.2M
- IPO Year
- MBWM 1997
- RGNX 2015
- Fundamental
- Price
- MBWM $46.46
- RGNX $13.24
- Analyst Decision
- MBWM Buy
- RGNX Strong Buy
- Analyst Count
- MBWM 4
- RGNX 7
- Target Price
- MBWM $52.88
- RGNX $30.29
- AVG Volume (30 Days)
- MBWM 55.7K
- RGNX 550.7K
- Earning Date
- MBWM 10-21-2025
- RGNX 11-06-2025
- Dividend Yield
- MBWM 3.37%
- RGNX N/A
- EPS Growth
- MBWM 6.26
- RGNX N/A
- EPS
- MBWM 5.27
- RGNX N/A
- Revenue
- MBWM $233,714,000.00
- RGNX $161,318,000.00
- Revenue This Year
- MBWM $10.44
- RGNX $198.02
- Revenue Next Year
- MBWM $11.11
- RGNX $2.67
- P/E Ratio
- MBWM $8.55
- RGNX N/A
- Revenue Growth
- MBWM 5.19
- RGNX 91.30
- 52 Week Low
- MBWM $37.76
- RGNX $5.04
- 52 Week High
- MBWM $52.98
- RGNX $13.93
- Technical
- Relative Strength Index (RSI)
- MBWM 58.66
- RGNX 64.51
- Support Level
- MBWM $43.40
- RGNX $10.76
- Resistance Level
- MBWM $45.80
- RGNX $12.05
- Average True Range (ATR)
- MBWM 1.29
- RGNX 0.80
- MACD
- MBWM 0.22
- RGNX 0.16
- Stochastic Oscillator
- MBWM 77.33
- RGNX 83.23
About MBWM Mercantile Bank Corporation
Mercantile Bank Corp operates as a bank holding company. It offers various commercial banking services to individuals, businesses, governmental units, and other institutions. These services include deposit products such as checking, savings, and term certificate accounts and lending products such as commercial, residential mortgage, and installment loans. The company generates revenue from interest and dividends earned on loans, securities, and other financial instruments.
About RGNX REGENXBIO Inc.
Regenxbio Inc is a biotechnology company. Its main activity is the development and commercialization of recombinant adeno associated virus gene therapy to correct an underlying genetic defect. The diseases that the Regenxbio platform targets are metabolic (homozygous familial hypercholesterolemia), neurodegenerative conditions (mucopolysaccharidosis), and retinal diseases (wet age-related macular degeneration, X-linked retinitis pigmentosa). The company derives the majority of its revenue from the United States.